Results 131 to 140 of about 38,007 (143)

Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic

Journal of the Neurological Sciences, 2021
Nello Blaser, Kjell-Morten Myhr, Gerd Haga Bringeland   +2 more
exaly  

Potential Nephrotoxicity of Both Conventional Interval Dosing and Extended Interval Dosing of Gentamycin in Preterm Infants

Mansoura Journal of Forensic Medicine and Clinical Toxicology, 2005
Essam Ali, Basma Shouman
openaire   +1 more source

Progressive Multifocal Leukoencephalopathy Associated to Natalizumab Extended Dosing Regimen

Neurodegenerative Disease Management, 2015
Cristina Ramo-Tello, Silvia Presas-Rodriguez   +1 more
exaly  

Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world

Expert Opinion on Drug Safety, 2023
exaly  

Application of Bayes Theorem to Aminoglycoside-Associated Nephrotoxicity: Comparison of Extended-Interval Dosing, Individualized Pharmacokinetic Monitoring, and Multiple-Daily Dosing

Journal of Clinical Pharmacology, 2004
Joseph S Bertino
exaly  

Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia

Current Medical Research and Opinion, 2006
Lucio Gordan, David Henry, Richard C Woodman   +2 more
exaly  

EXTENDED INTERVAL DOSING OF NATALIZUMAB

2019
CAMPBELL NOLAN ROBERT, CHANG IH, KANDADI MURALIDHARAN BHARATH KUMAR, NESTOROV IVAN ALEXANDROV   +3 more
openaire   +3 more sources

Critical issues in recommending extended interval dosing

Multiple Sclerosis and Related Disorders
openaire   +2 more sources

Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With Psoriasis

JAMA Dermatology
Andrew, Blauvelt, Curdin, Conrad, Megan H, Noe   +2 more
openaire   +2 more sources

Early extended interval dosing of rituximab in multiple sclerosis: A comparative cohort study on efficacy and safety

Multiple Sclerosis and Related Disorders
Øivind Torkildsen, Lars Bø, Kjell-Morten Myhr   +2 more
exaly